Chemours (NYSE:CC) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Several other equities research analysts also recently issued reports on the stock. Citigroup upgraded shares of Chemours from a “neutral” rating to a “buy” rating in a research report on Friday, January 4th. HSBC initiated coverage on shares of Chemours in a research report on Tuesday, January 8th. They set a “buy” rating and a $52.00 price objective for the company. Barclays restated a “buy” rating and set a $48.00 price objective on shares of Chemours in a research report on Tuesday, January 15th. Zacks Investment Research upgraded shares of Chemours from a “sell” rating to a “hold” rating in a research report on Tuesday, December 11th. Finally, SunTrust Banks raised their price objective on shares of Chemours to $40.00 and gave the stock a “hold” rating in a research report on Tuesday, February 19th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $48.13.

Shares of Chemours stock traded up $0.60 during trading hours on Wednesday, reaching $39.99. 2,329,400 shares of the company’s stock were exchanged, compared to its average volume of 1,639,909. Chemours has a fifty-two week low of $25.17 and a fifty-two week high of $53.25. The company has a debt-to-equity ratio of 3.88, a current ratio of 1.93 and a quick ratio of 1.26. The company has a market cap of $6.65 billion, a price-to-earnings ratio of 7.05, a P/E/G ratio of 0.54 and a beta of 2.31.

Chemours (NYSE:CC) last issued its earnings results on Thursday, February 14th. The specialty chemicals company reported $1.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.04 by $0.01. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a net margin of 14.99% and a return on equity of 98.83%. Chemours’s revenue was down 7.0% on a year-over-year basis. During the same period last year, the business posted $1.19 EPS. As a group, sell-side analysts expect that Chemours will post 4.69 earnings per share for the current year.

In other news, insider Paul Kirsch sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $38.66, for a total transaction of $386,600.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Mark Newman sold 59,210 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $38.26, for a total transaction of $2,265,374.60. Following the transaction, the vice president now directly owns 94,261 shares in the company, valued at $3,606,425.86. The disclosure for this sale can be found here. Insiders have sold 101,924 shares of company stock worth $3,924,730 over the last ninety days. Insiders own 1.75% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Financial Architects Inc increased its stake in Chemours by 39.2% in the fourth quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock valued at $40,000 after acquiring an additional 400 shares during the last quarter. Lavaca Capital LLC bought a new position in Chemours in the fourth quarter valued at approximately $44,000. FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in Chemours by 357.1% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 3,200 shares of the specialty chemicals company’s stock valued at $90,000 after acquiring an additional 2,500 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in Chemours by 3,583.3% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 2,675,256 shares of the specialty chemicals company’s stock valued at $95,000 after acquiring an additional 2,602,624 shares during the last quarter. Finally, Penserra Capital Management LLC increased its stake in Chemours by 122.6% in the fourth quarter. Penserra Capital Management LLC now owns 4,167 shares of the specialty chemicals company’s stock valued at $116,000 after acquiring an additional 2,295 shares during the last quarter. 79.30% of the stock is currently owned by institutional investors.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Read More: Insider Trading – What You Need to Know

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.